# Mitrix Bio

> Mitrix Bio is a Bay Area biotech startup building bioreactor-grown mitochondria - the cell's power plants - packaged into vesicles it calls 'Mitlets' and delivered by injection. Founded by former SLAC accelerator manager Tom Benson, the company treats the slow decline of mitochondria as a root cause of aging and aims to manufacture autologous, young mitochondria at industrial scale so clinicians can regenerate organs, boost immunity and cognition, and extend healthy human lifespan toward 130 years.

- **Founded:** 2018
- **Headquarters:** Pleasanton, California, United States
- **Founders:** Tom Benson (Founder & CEO)
- **Team size:** ~11 employees
- **Products:** Mitlets, Autologous mitochondrial transplantation, MitoClock
- **Notable:** Raised $250,000 pre-seed funding in January 2021 from R42 and Longevity Tech Fund, Reported transplantation tests with results in immune system, retina, brain, and skin, Assembled academic advisors and collaborators from Stanford, UCLA, University of Kentucky, and University of Manitoba

## Products & services

- **Mitlets** — Young, bioreactor-grown mitochondria encased in vesicles (exosome-like membranes) so they can be absorbed by cells after injection into the blood or tissue.
- **Autologous mitochondrial transplantation** — A process that harvests a patient's own stem cells from blood or fat, amplifies them roughly 10,000x in a bioreactor, extracts their mitochondria, and transplants them back into the same patient.
- **MitoClock** — The company's framing of aging as a mitochondrial 'clock' - a countdown of declining cellular energy that mitochondrial supplementation aims to reset.

## Achievements

- Raised $250,000 pre-seed funding in January 2021 from R42 and Longevity Tech Fund
- Reported transplantation tests with results in immune system, retina, brain, and skin
- Assembled academic advisors and collaborators from Stanford, UCLA, University of Kentucky, and University of Manitoba
- Launched a first-in-human volunteer trial in 2025, beginning with a 90-year-old physicist

## Latest updates

- **2021-01** — Secured $250,000 pre-seed funding for 'whole-body mitochondrial transfusion' technology.
- **2024-12** — Refreshed website presence with new Mitlets and bioreactor visuals and science explainers.
- **2025-07** — Announced a volunteer mitochondrial transplantation trial; first participant is 90-year-old emeritus physicist John G. Cramer, with collaborators from Stanford, UCLA, and Northwell Health.
- **2025-08** — Trial slated to begin August 1, 2025, seeking up to five more volunteers aged 55+ or with chronic conditions.

## Links

- Website: https://mitrix.bio
- LinkedIn: https://www.linkedin.com/company/mitochondrial-transplant
- YouTube: https://www.youtube.com/watch?v=KonKMqMatkY

---

Profile page: https://yespress.io/mitrix-bio
Published by YesPress — https://yespress.io
Last updated: 2026-08-03